Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

PARP inhibitors potentiate cytotoxicity of alkylating agents, bleomycin and radiation

Jan. 20, 1999

New formulation may facilitate clinical development of antagonist G

Jan. 20, 1999

XK-469, an analogue of the herbicide Assure, in clinical testing as antitumor agent

Jan. 20, 1999

Potential new use for Anticort to be tested in Romania

Jan. 20, 1999

Cell Pathways explores SAANDs as new class of anticancer drugs; patent issues in U.S.

Jan. 19, 1999

Dose of O6-benzylguanine for use with BCNU in brain cancer patients determined

Jan. 19, 1999

Relationship between antitumor activity of bombesin/GRP antagonists and effects on EGF receptors

Jan. 19, 1999

Cancer Research Campaign Technology evaluates new antitumor trimelamol analogues

Jan. 19, 1999

Tricyclic antiproliferative agents revealed by Schering-Plough

Jan. 19, 1999

Antitumor candidate originating in Kazakstan slated for development in U.S. and other countries

Jan. 18, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.